235 related articles for article (PubMed ID: 25554400)
21. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence.
Fanouriakis A; Kougkas N; Vassilopoulos D; Fragouli E; Repa A; Sidiropoulos P
Semin Arthritis Rheum; 2015 Aug; 45(1):60-6. PubMed ID: 25908179
[TBL] [Abstract][Full Text] [Related]
22. Activation of natural killer cells by rituximab in granulomatosis with polyangiitis.
Urlaub D; Zhao S; Blank N; Bergner R; Claus M; Tretter T; Lorenz HM; Watzl C; Merkt W
Arthritis Res Ther; 2019 Dec; 21(1):277. PubMed ID: 31829278
[TBL] [Abstract][Full Text] [Related]
23. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
Gause AM; Rubbert-Roth A;
Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
[TBL] [Abstract][Full Text] [Related]
24. Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener's).
You C; Ma L; Lasave AF; Foster CS
Ocul Immunol Inflamm; 2018; 26(8):1166-1173. PubMed ID: 28628344
[TBL] [Abstract][Full Text] [Related]
25. Long-term B-lymphocyte depletion and remission of granulomatosis with polyangiitis after two courses of rituximab treatment.
Valor-Méndez L; Kleyer A; Rech J; Manger B; Schett G
Rheumatology (Oxford); 2021 May; 60(5):e162-e164. PubMed ID: 33232468
[No Abstract] [Full Text] [Related]
26. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
[TBL] [Abstract][Full Text] [Related]
27. Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis.
Bussone G; Kaswin G; de Menthon M; Delair E; Brézin AP; Guillevin L
Clin Exp Rheumatol; 2010; 28(1 Suppl 57):90-2. PubMed ID: 20412711
[TBL] [Abstract][Full Text] [Related]
28. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
29. Pachymeningitis and cerebral granuloma in granulomatosis with polyangiitis: is rituximab a promising treatment option?
Costa C; Santiago T; Espirito-Santo J; Rovisco J; Silva J; Malcata A
Acta Reumatol Port; 2017; 42(1):82-87. PubMed ID: 28371573
[TBL] [Abstract][Full Text] [Related]
30. Treatment of granulomatosis with polyangiitis (Wegener's).
Pagnoux C; Guillevin L
Expert Rev Clin Immunol; 2015 Mar; 11(3):339-48. PubMed ID: 25644677
[TBL] [Abstract][Full Text] [Related]
31. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
32. Biological drugs in ANCA-associated vasculitis.
Lutalo PM; D'Cruz DP
Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of gynaecological involvement of granulomatosis with polyangiitis (Wegener's granulomatosis) by rituximab.
Bastone P; Squifflet JL; Marbaix E; Houssiau F
Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-142-4. PubMed ID: 26016766
[TBL] [Abstract][Full Text] [Related]
34. Granulomatosis with polyangiitis with intestinal involvement successfully treated with rituximab and surgery.
Sato H; Shima K; Sakata H; Ohtoh T
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31401575
[TBL] [Abstract][Full Text] [Related]
35. The Paradoxical Reaction to Rituximab in Six Granulomatosis with Polyangiitis Patients: How Could it be Explained and Managed?
Alesaeidi S; Piri SM; Tavakolpour S
Curr Rheumatol Rev; 2021 Aug; 17(3):327-330. PubMed ID: 33605863
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.
Aouba A; Pagnoux C; Bienvenu B; Mahr A; Guillevin L
Clin Rev Allergy Immunol; 2008 Feb; 34(1):65-73. PubMed ID: 18270860
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Mohammad AJ; Hot A; Arndt F; Moosig F; Guerry MJ; Amudala N; Smith R; Sivasothy P; Guillevin L; Merkel PA; Jayne DR
Ann Rheum Dis; 2016 Feb; 75(2):396-401. PubMed ID: 25467294
[TBL] [Abstract][Full Text] [Related]
38. Successful use of rituximab in granulomatosis with polyangiitis with aortic inflammation.
Pineda Bernal L; Bitencourt N; Batra K; Solow EB
Clin Exp Rheumatol; 2019; 37 Suppl 117(2):144-147. PubMed ID: 30299239
[TBL] [Abstract][Full Text] [Related]
39. Orbital presentation of systemic vasculitis: a diagnostic and management challenge.
Singh M; Singh U; Zadeng Z
Nepal J Ophthalmol; 2015; 7(1):65-8. PubMed ID: 26695609
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of rituximab in rheumatic diseases.
Rath E; Zwerina J; Oppl B; Nell-Duxneuner V
Wien Med Wochenschr; 2015 Jan; 165(1-2):28-35. PubMed ID: 25676699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
